CN106606779A - Edible film tablet and preparation method thereof - Google Patents
Edible film tablet and preparation method thereof Download PDFInfo
- Publication number
- CN106606779A CN106606779A CN201510675975.9A CN201510675975A CN106606779A CN 106606779 A CN106606779 A CN 106606779A CN 201510675975 A CN201510675975 A CN 201510675975A CN 106606779 A CN106606779 A CN 106606779A
- Authority
- CN
- China
- Prior art keywords
- parts
- diaphragm
- edibility
- weight
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides an edible film tablet and a preparation method thereof, wherein the edible film table is adopted as a pharmaceutically active component carrier. According to the present invention, cellulose, gelatin and polysaccharide are adopted as raw materials and other additives are combined to prepare a layer of the edible film tablet, and the active components of drugs are uniformly adhered to the edible film tablet under the mixing of a water-soluble polymer so as to form a new pharmaceutical dosage form; with the novel edible drug film tablet technology, the partial drugs can be prepared into the dosage form with characteristics of easy carrying and easy taking; and peppermint can be added to the edible film tablet to prepare the completely-new film dosage form with the refreshing taste, wherein the obtained dosage form is particularly suitable for medication in children.
Description
Technical field
The present invention relates to technical field of medicine packaging, can be used as the edible of pharmaceutical carrier more particularly to a kind of
Property diaphragm and preparation method thereof.
Background technology
In recent years, edible packing membrane has become class more popular during Medicine packaging material are studied
Topic.Constantly there are new product and technology to occur both at home and abroad.Edible packing membrane is one kind with edibility material
For main matrix, be aided with edibility plasticizer, phase between each flim forming molecule is made through certain handling process
Interaction, the compact structure with certain mechanical property and selective penetrated property for being formed after the drying it is thin
Film.Existing edible film chip technology, is intended only as a kind of inner packing of food, does not play medicine load
The effect of body.
In a further aspect, medical novel form and novel medicine feeding technology are also being constantly updated.At present most
During new improving dosage form, a part of medicine is transformed into into edibility diaphragm from tablet and capsule form,
Compare conventional medicament and have easy to carry, take simple, the benefit such as taste is pure and fresh.Meanwhile, the system of medicine
Making technique reduces the addition and use of adjuvant, reduces production cost.Have been reported that and diaphragm is made into multilamellar
Tabletting, medicine is wrapped up wherein.However, the function that this diaphragm does not controllably discharge.Diaphragm exists
Dissolve in oral cavity, medicine discharges immediately, effective ingredient is just destroyed under one's belt, it is impossible to enters and makees
Worked with position.Therefore, existing edible film chip technology may be only available for the medicine of sublingual administration.
The content of the invention
For problem present in present technology, the present invention develops a kind of new edibility diaphragm, and which was both
Can be used as the inner packing of novel medicine feeding dosage form, but the active component for medicine provides a kind of medicine load
Body.And, the edibility diaphragm prepared using the composition and technique of the present invention can tolerate invading for gastric acid
Effective ingredient is delivered to position of working by erosion.The technology of the present invention causes this edibility diaphragm not
Only become a kind of wrapping tool, and become the core component of this novel pharmaceutical formulation.
One aspect of the present invention provides a kind of edibility diaphragm, counts by weight, the edibility diaphragm
Including：
15～25 parts of gelatin, 7～17 parts of low viscosity pectin, 40～60 parts of pulullan polysaccharide, cellulose
27～85 parts of binding agent, 10～20 parts of sodium alginate, 5～15 parts of casein, 5～15 parts of Oleum Brassicae campestriss,
5～15 parts of 5～15 parts of agar, 10～20 parts of zein and carrageenan.
Preferably, count by weight, the cellulosic binders include hydroxypropyl methylcellulose 20～30
Part, 5～15 parts of hydroxypropyl cellulose, 2～7 parts of sodium carboxymethyl cellulose.
Preferably, count by weight, the cellulosic binders include hydroxy alkyl cellulose 25～35
Part, 15～25 parts of Polyethylene Glycol, 10～25 parts of polypropylene glycol.It is highly preferred that the hydroxylalkyl
Element is hydroxypropyl methylcellulose and/or hydroxypropyl cellulose.
Preferably, in a kind of embodiment of the edibility diaphragm of the present invention, the edibility diaphragm is also
Including 70～90 parts of the plant amylum counted by weight.
It is highly preferred that in a kind of embodiment of the edibility diaphragm of the present invention, the edibility diaphragm
Further include 3～7 parts of the Herba Menthae counted by weight.
Another aspect of the present invention provides a kind of method for preparing the edibility diaphragm, and methods described includes
Following steps：
(1) 800～1200 parts of the water counted by weight is heated to into 70～80 DEG C, and in this temperature
Lower stirring 1～2 hour；
(2) and then in solution add count by weight 15～25 parts of gelatin, low viscosity pectin 7～
17 parts, 40～60 parts of pulullan polysaccharide, 27～85 parts of cellulosic binders, sodium alginate 10～20
Part, 5～15 parts of casein；The mixture for obtaining is warming up to into 90～95 DEG C, and stirs 1～2 hour；
Add at a temperature of 90～95 DEG C 5～15 parts of Oleum Brassicae campestriss, 5～15 parts of agar, zein 10～
20 parts, 5～15 parts of carrageenan, add insulation 1～2 hour；
(3) by mixed liquor cooling down to room temperature, it is sufficiently mixed uniformly, is filtrated to get filtrate；
(4) by filtrate homogenous disperse 30～60 minutes, then filtrate is coated on macromolecular material base material,
It is dried at 30～40 DEG C of temperature and 65 ± 5% ambient humidity, to form diaphragm；
Preferably, methods described also includes step (5)：After taking off film, by diaphragm be placed on temperature for 25～
30 DEG C and ambient humidity be 55～65% hermetic container in store.
Preferably, the cellulosic binders include any one in following combination：(a) hydroxypropyl
20～30 parts of methylcellulose, 5～15 parts of hydroxypropyl cellulose, 2～7 parts of sodium carboxymethyl cellulose；
25～35 parts of (b) hydroxy alkyl cellulose, 15～25 parts of Polyethylene Glycol, 10～25 parts of polypropylene glycol；
It is highly preferred that the hydroxy alkyl cellulose is hydroxypropyl methylcellulose and/or hydroxypropyl cellulose.
Preferably, in above-mentioned steps (1), the plant amylum 70～90 counted by weight is added in water
Part is simultaneously heated to 70～80 DEG C together.
Preferably, in above-mentioned steps (3), after mixeding liquid temperature is down to room temperature, add by weight
3～7 portions of Herba Menthaes of number meter, are then sufficiently mixed, are finally filtrated to get filtrate.
Preferably, in above-mentioned steps (4), the macromolecular material base material is water-soluble plant source
Alcohol in one or more combination；It is highly preferred that the alcohol in the water-soluble plant source is selected from red moss
Alcohol and phytol.
The edibility diaphragm of the present invention acts not only as the inner packaging material of effective ingredient, and
By the bonding of water-soluble cellulose binding agent, the carrier of medicine is also used as, reduces or get rid of completely
Abandon the use of the adjunct ingredient such as starch, sugar-coat in Conventional solid preparation, play reduction adjuvant and producing cost,
Increase patient compliance, it is convenient for carrying and takes etc. benefit.Furthermore it is also possible in the diaphragm of the present invention
Herba Menthae is added, the pure and fresh brand-new thin-film dosage form of taste is prepared into, is particularly well-suited to children.
The edibility diaphragm of the present invention can tolerate the erosion of gastric acid, effective ingredient is delivered to and is worked
Position.Wherein, the combination of gelatin, pectin and/or several celluloses so that diaphragm is presented alkalescence, real
Test obtains diaphragm in a liquid state, and pH value is 7.9, and this acid-base value serves part protection medicine and exists
Do not acted on by sour corrosion in gastric juice, so that the effective ingredient of medicine arrives at site of action, fully sent out
Wave therapeutic effect.
Specific embodiment
The present invention is further illustrated with reference to embodiments.It should be appreciated that following embodiments are only to this
That what is invented further elucidates, rather than limitation of the present invention.
Experimental technique in following embodiments, if no special instructions, is conventional method.Following enforcements
In example, raw material used, reagent material etc., if no special instructions, are commercially available purchase product.
Embodiment 1
Prepare the raw material following (counting by weight) of the present embodiment edibility diaphragm：
20 parts of gelatin, 12 parts of low viscosity pectin, 50 parts of pulullan polysaccharide, hydroxypropyl methylcellulose 25
Part, 10 parts of hydroxypropyl cellulose, 5 parts of sodium carboxymethyl cellulose, 15 parts of sodium alginate, casein 10
Part, 10 parts of Oleum Brassicae campestriss, 10 parts of agar, 15 parts of zein, 10 parts of carrageenan, plant amylum 80
Part, 1000 parts of water.Material therefor is food stage.
The preparation method of the present embodiment edibility diaphragm comprises the steps：
(1) 80 parts of plant amylums are added in 1000 parts of water, is heated to 70～80 DEG C, in this temperature
Lower stirring 1～2 hour.
(2) successively in solution add 20 parts of gelatin, 12 parts of low viscosity pectin, pulullan polysaccharide 50
Part, 25 parts of hydroxypropyl methylcellulose, 10 parts of hydroxypropyl cellulose, 5 parts of sodium carboxymethyl cellulose, sea
The mixture for obtaining is warming up to 90～95 DEG C by 15 parts of sodium alginate, 10 parts of casein, stirring 1～2
Hour.10 parts of Oleum Brassicae campestriss, 10 parts of agar, zein 15 are added at a temperature of 90～95 DEG C
Part, 10 parts of carrageenan, add and are incubated 1～2 hour at 90～95 DEG C.
(3) by mixed liquor cooling down, drop to room temperature and be sufficiently mixed uniformly, be finally filtrated to get filtrate.
(4) by filtrate homogenous disperse 30～60 minutes, then filtrate is coated on erithritol base material,
Cool drying one day at 30～40 DEG C of temperature and 65 ± 5% ambient humidity, to form diaphragm.
(5), after taking off film, diaphragm be placed on temperature to be 25～30 DEG C to be 55～65% with ambient humidity
Store in hermetic container.According to the medicine of connected applications, the thickness of the diaphragm for obtaining can be in 0.5～1mm
Between.
Although the diaphragm of the present embodiment 1 also using plant amylum, but for whole diaphragm, plant
The proportion of thing starch is low-down.The diaphragm of this enforcement is applicable to part urogenital organ's medication,
Such as medicines such as Sildenafil Citrate, Ta Dalafei.
Embodiment 2
Prepare the raw material following (counting by weight) of the present embodiment edibility diaphragm：
15 parts of gelatin, 17 parts of low viscosity pectin, 60 parts of pulullan polysaccharide, hydroxypropyl methylcellulose 35
Part, 15 parts of Polyethylene Glycol, 20 parts of polypropylene glycol, 20 parts of sodium alginate, 5 parts of casein, Semen Allii Tuberosi
5 parts of oil, 15 parts of agar, 20 parts of zein, 5 parts of carrageenan, 1200 parts of water.
The preparation method of the present embodiment edibility diaphragm comprises the steps：
(1) 1200 parts of water are heated to into 70～80 DEG C, are stirred 1～2 hour at this temperature.
(2) successively in solution add 15 parts of gelatin, 17 parts of low viscosity pectin, pulullan polysaccharide 60
Part, 35 parts of hydroxypropyl methylcellulose, 15 parts of Polyethylene Glycol, 20 parts of polypropylene glycol, sodium alginate 20
The mixture for obtaining is warming up to 90～95 DEG C by part, 5 parts of casein, is stirred 1～2 hour.90
5 parts of Oleum Brassicae campestriss, 15 parts of agar, 20 parts of zein, carrageenan 5 are added at a temperature of～95 DEG C
Part, add 1～2 hour is incubated at 90～95 DEG C.
(3) by mixed liquor cooling down to room temperature.It is sufficiently mixed uniformly, is finally filtrated to get filtrate.
(4) by filtrate homogenous disperse 30～60 minutes, then filtrate is coated on phytol base material,
Cool drying one day at 30～40 DEG C of temperature and 65 ± 5% ambient humidity, to form diaphragm.
(5), after taking off film, diaphragm be placed on temperature to be 25～30 DEG C to be 55～65% with ambient humidity
Store in hermetic container.According to the medicine of connected applications, the thickness of the diaphragm for obtaining can be in 0.5～1mm
Between.
The diaphragm of the present embodiment has thoroughly abandoned starch component, and is primarily adapted for use in old medication, such as anti-
Alzheimer disease drugs donepezil hydrochloride.
Embodiment 3
Prepare the raw material following (counting by weight) of the present embodiment edibility diaphragm：
25 parts of gelatin, 7 parts of low viscosity pectin, 40 parts of pulullan polysaccharide, 25 parts of hydroxypropyl cellulose,
25 parts of Polyethylene Glycol, 10 parts of polypropylene glycol, 10 parts of sodium alginate, 15 parts of casein, Oleum Brassicae campestriss 15
Part, 5 parts of agar, 10 parts of zein, 15 parts of carrageenan, 70 parts of plant amylum, 5 parts of Herba Menthae,
800 parts of water.
The preparation method of the present embodiment edibility diaphragm comprises the steps：
(1) 70 parts of plant amylums are added in 800 parts of water, is heated to 70～80 DEG C, at this temperature
Stirring 1～2 hour.
(2) successively in solution add 25 parts of gelatin, 7 parts of low viscosity pectin, pulullan polysaccharide 40
Part, 25 parts of hydroxypropyl cellulose, 25 parts of Polyethylene Glycol, 10 parts of polypropylene glycol, 10 parts of sodium alginate,
15 parts of casein, mixture are warming up to 90～95 DEG C, stir 1～2 hour.In 90～95 DEG C of temperature
15 parts of Oleum Brassicae campestriss, 5 parts of agar, 10 parts of zein, 15 parts of carrageenan are added under degree, is added
1～2 hour is incubated at 90～95 DEG C.
(3) 5 portions of Herba Menthaes will be added after mixed liquor cooling down to room temperature, will be sufficiently mixed uniformly, finally
It is filtrated to get filtrate.
(4) by filtrate homogenous disperse 30～60 minutes, then filtrate is coated on erithritol base material,
Cool drying one day at 30～40 DEG C of temperature and 65 ± 5% ambient humidity, to form diaphragm.
(5), after taking off film, diaphragm be placed on temperature to be 25～30 DEG C to be 55～65% with ambient humidity
Store in hermetic container.According to the medicine of connected applications, the thickness of the diaphragm for obtaining can be in 0.5～1mm
Between.
The diaphragm of the present embodiment adds Herba Menthae, improves the sense of taste of medicine, is highly suitable for children
Such as antiprotozoal drug primaquine phosphate, and vitimin supplement class medicine such as maltose hydroxide iron salt.
Claims (10)
1. a kind of edibility diaphragm, is counted by weight, and the edibility diaphragm includes：
15～25 parts of gelatin, 7～17 parts of low viscosity pectin, 40～60 parts of pulullan polysaccharide, cellulose
27～85 parts of binding agent, 10～20 parts of sodium alginate, 5～15 parts of casein, 5～15 parts of Oleum Brassicae campestriss,
5～15 parts of agar, 10～20 parts of zein, 5～15 parts of carrageenan.
2. edibility diaphragm according to claim 1, it is characterised in that count by weight, institute
State cellulosic binders include 20～30 parts of hydroxypropyl methylcellulose, 5～15 parts of hydroxypropyl cellulose,
2～7 parts of sodium carboxymethyl cellulose.
3. edibility diaphragm according to claim 1, it is characterised in that count by weight, institute
State cellulosic binders include 25～35 parts of hydroxy alkyl cellulose, 15～25 parts of Polyethylene Glycol, poly- the third two
10～25 parts of alcohol.
4. edibility diaphragm according to claim 3, it is characterised in that the hydroxy alkyl cellulose
For hydroxypropyl methylcellulose and/or hydroxypropyl cellulose.
5. edibility diaphragm according to claim 1, it is characterised in that the edibility diaphragm is also
Including 70～90 parts of the plant amylum counted by weight.
6. edibility diaphragm according to claim 1, it is characterised in that the edibility diaphragm enters
One step includes 3～7 parts of the Herba Menthae counted by weight.
7. a kind of method of the edibility diaphragm prepared as described in any one of claim 1-6, methods described
Comprise the steps：
(1) 800～1200 parts of the water counted by weight is heated to into 70～80 DEG C, and in this temperature
Lower stirring 1～2 hour；
(2) and then in solution add count by weight 15～25 parts of gelatin, low viscosity pectin 7～
17 parts, 40～60 parts of pulullan polysaccharide, 27～85 parts of cellulosic binders, sodium alginate 10～20
Part, 5～15 parts of casein；The mixture for obtaining is warming up to into 90～95 DEG C, is stirred 1～2 hour；
Add at a temperature of 90～95 DEG C 5～15 parts of Oleum Brassicae campestriss, 5～15 parts of agar, zein 10～
20 parts, 5～15 parts of carrageenan, add insulation 1～2 hour；
(3) by mixed liquor cooling down to room temperature, it is sufficiently mixed uniformly, is filtrated to get filtrate；
(4) by filtrate homogenous disperse 30～60 minutes, then filtrate is coated on macromolecular material base material,
It is dried at 30～40 DEG C of temperature and 65 ± 5% ambient humidity, to form diaphragm；
(5) optionally, after taking off film, it is 55 with ambient humidity that diaphragm is placed on temperature for 25～30 DEG C
Store in～65% hermetic container；
Preferably, in the step (4), the macromolecular material base material is water-soluble plant source
Alcohol in one or more combination；It is highly preferred that the alcohol in the water-soluble plant source is selected from red moss
Alcohol and phytol.
8. method according to claim 7, it is characterised in that the cellulosic binders are selected from such as
Any one combination in lower combination：20～30 parts of (a) hydroxypropyl methylcellulose, hydroxypropyl cellulose 5～
15 parts, 2～7 parts of sodium carboxymethyl cellulose；25～35 parts of (b) hydroxy alkyl cellulose, Polyethylene Glycol
15～25 parts, 10～25 parts of polypropylene glycol.
9. method according to claim 7, it is characterised in that in the step (1),
70～90 parts of the plant amylum counted by weight is added in water and 70～80 DEG C are heated to together.
10. method according to claim 9, it is characterised in that in the step (3), mixes
After conjunction liquid temp is down to room temperature, 3～7 portions of Herba Menthaes counted by weight is added, are then sufficiently mixed,
Filtrate is filtrated to get finally.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510675975.9A CN106606779A (en) | 2015-10-19 | 2015-10-19 | Edible film tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510675975.9A CN106606779A (en) | 2015-10-19 | 2015-10-19 | Edible film tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106606779A true CN106606779A (en) | 2017-05-03 |
Family
ID=58611115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510675975.9A Pending CN106606779A (en) | 2015-10-19 | 2015-10-19 | Edible film tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106606779A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040247744A1 (en) * | 2002-02-11 | 2004-12-09 | Edizone, Lc | Vitamin-containing orally soluble films |
| US20090004254A1 (en) * | 2007-06-19 | 2009-01-01 | Todd Maibach | Film comprising active drugs |
| CN101626757A (en) * | 2007-03-05 | 2010-01-13 | 麦克内尔-Ppc股份有限公司 | Fast-dissolving/disintegrating film preparation having high proportion of active |
| CN102333526A (en) * | 2009-06-25 | 2012-01-25 | Cha生物&Diostech株式会社 | Fast-dissolving oral film for effectively concealing unpleasant tastes |
| CN104586820A (en) * | 2015-01-13 | 2015-05-06 | 齐鲁制药有限公司 | Sildenafil rapidly disintegrating film composition with high drug loading capacity |
-
2015
- 2015-10-19 CN CN201510675975.9A patent/CN106606779A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040247744A1 (en) * | 2002-02-11 | 2004-12-09 | Edizone, Lc | Vitamin-containing orally soluble films |
| CN101626757A (en) * | 2007-03-05 | 2010-01-13 | 麦克内尔-Ppc股份有限公司 | Fast-dissolving/disintegrating film preparation having high proportion of active |
| US20090004254A1 (en) * | 2007-06-19 | 2009-01-01 | Todd Maibach | Film comprising active drugs |
| CN102333526A (en) * | 2009-06-25 | 2012-01-25 | Cha生物&Diostech株式会社 | Fast-dissolving oral film for effectively concealing unpleasant tastes |
| CN104586820A (en) * | 2015-01-13 | 2015-05-06 | 齐鲁制药有限公司 | Sildenafil rapidly disintegrating film composition with high drug loading capacity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2807346B2 (en) | Orally disintegrating preparation and production method thereof | |
| KR101705204B1 (en) | Aqueous composition for hard capsule having enteric properties, method of preparing hard capsule having enteric properties and hard capsule prepared by the latter | |
| KR101161430B1 (en) | Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight | |
| PL197462B1 (en) | Fast dispersing dosage forms free of gelatin | |
| JP2000136126A (en) | Production of hard capsule | |
| CA2633924A1 (en) | Gastric reflux resistant dosage forms | |
| CN105434397A (en) | Vegetable soft capsule shell composition and preparation method thereof | |
| KR20080031037A (en) | Formulations of conjugated estrogens and bazedoxifene | |
| BR112019021391A2 (en) | pullulan capsules | |
| US20070184099A1 (en) | Films for use as dosage forms | |
| CN105919962A (en) | Dabigatran tablet, and preparation method and application thereof | |
| KR20010043408A (en) | Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates | |
| JP4851064B2 (en) | Pharmaceutical form for thyroid hormone and method for obtaining the same | |
| US20110269844A1 (en) | Thin film with propofol active ingredient | |
| CN106606779A (en) | Edible film tablet and preparation method thereof | |
| CN107412198A (en) | Duloxetine hydrochloride enteric slow release granule and preparation method thereof | |
| CN115429771B (en) | Composite glue for capsules and preparation method and application thereof | |
| CN106727378A (en) | A kind of tablet composition containing ticagrelor main ingredient and preparation method thereof | |
| KR100732199B1 (en) | Masticatable capsule and process for producing the same | |
| CN108272776B (en) | Amitriptyline hydrochloride oral instant film agent | |
| CN108309948A (en) | Cetirizine hydrochloride Tablets and preparation method thereof | |
| CN108283628A (en) | A kind of anticancer drug microcapsule formulation and preparation method thereof | |
| TW201524537A (en) | Aqueous composition for hard capsule and hard capsule prepared by using the same | |
| CN104758271A (en) | Plant vacant capsule compounded from cellulose gum and red alga KAPPA gum and preparation method thereof | |
| JP6267066B2 (en) | Controlled release soft capsule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170503 |
|
| WD01 | Invention patent application deemed withdrawn after publication |